此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Effects of Remimazolam on Postoperative Cognitive Dysfunction and Neuroinflammatory Biomarkers in Patients Undergoing Aortic Arch Surgery

2026年9月14日 更新者:Youn Joung Cho, MD, PhD、Seoul National University Hospital

Effects of Remimazolam on Postoperative Cognitive Dysfunction and Neuroinflammatory Biomarkers in Patients Undergoing Aortic Arch Surgery: A Randomized Controlled Trial

The purpose of this study is to compare remimazolam- and propofol-based anesthesia for their effects on postoperative cognitive dysfunction in patients undergoing aortic arch surgery. These procedures involve a substantial risk of cerebral ischemia and reperfusion injury, which may contribute to postoperative cognitive decline. Although experimental studies have suggested potential neuroprotective effects of remimazolam, clinical evidence in patients undergoing high-risk aortic arch surgery remains limited. This prospective, randomized controlled trial will compare the incidence of postoperative cognitive dysfunction between patients receiving remimazolam- or propofol-based anesthesia. In addition, changes in circulating neuroinflammatory and neuronal injury biomarkers will be evaluated to explore the potential mechanisms underlying any neuroprotective effect of remimazolam. The findings may provide clinical evidence to guide anesthetic selection and improve neurological outcomes in patients undergoing aortic arch surgery.

研究概览

研究类型

介入性

注册 (估计的)

80

阶段

  • 第四阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Youn Joung Cho, M.D., Ph.D.
  • 电话号码:82-2-2072-2467
  • 邮箱:mingming7@gmail.com

学习地点

      • Seoul、韩国、03080
        • Seoul National University Hospital
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • Adults aged 19 years or older
  • Patients scheduled to undergo total or partial aortic arch replacement for aortic arch disease, with planned circulatory arrest and/or selective cerebral perfusion as a cerebral protection strategy during surgery

Exclusion Criteria:

  • Pre-existing cognitive impairment, defined as Mini-Mental State Examination (MMSE) score <24
  • Acute cerebral hemorrhage or cerebral infarction within the previous 3 months
  • History of hypersensitivity to remimazolam or other benzodiazepines
  • History of alcohol or substance abuse
  • Chronic use of opioids or benzodiazepines
  • Severe hepatic impairment (Child-Pugh class C)
  • Acute or chronic renal failure requiring dialysis Emergency surgery or acute aortic dissection

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:Remimazolam group
Remimazolam Besylate (2mg/mL)
- Continuous drug: remimazolam diluted to 2 mg/mL in normal saline - Maintenance: 1-2 mg/kg/h (titrated to BIS 40-60, max 2 mg/kg/h)
实验性的:Propofol group
Propofol (20mg/mL)
Continuous drug: propofol (undiluted, 20 mg/mL) - Administration: target-controlled infusion (TCI, Marsh model) - Maintenance: 1-1.5 μg/mL (titrated to BIS 40-60)

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Incidence of postoperative cognitive decline
大体时间:Preoperative baseline to postoperative day 7 or before hospital discharge
Postoperative cognitive function will be assessed using the Korean Mini-Mental State Examination (K-MMSE) and the Korean version of the Montreal Cognitive Assessment (MoCA-K). Both assessments will be performed preoperatively and again on postoperative day 7 or before hospital discharge. Postoperative cognitive dysfunction will be defined as a decrease of ≥2 points from the preoperative baseline score in either the K-MMSE or MoCA-K.
Preoperative baseline to postoperative day 7 or before hospital discharge

次要结果测量

结果测量
措施说明
大体时间
Change in plasma IL-1β concentration
大体时间:Preoperative baseline to 2-4 hours after completion of cardiopulmonary bypass
Plasma interleukin-1 beta (IL-1β) concentration will be measured at preoperative baseline and 2-4 hours after completion of cardiopulmonary bypass. The change from baseline will be compared between the remimazolam and propofol groups. Plasma IL-1β concentration will be measured in pg/mL using the Meso Scale Discovery assay.
Preoperative baseline to 2-4 hours after completion of cardiopulmonary bypass
Change in plasma TNF-α concentration
大体时间:Preoperative baseline to 2-4 hours after completion of cardiopulmonary bypass
Plasma tumor necrosis factor-alpha (TNF-α) concentration will be measured at preoperative baseline and 2-4 hours after completion of cardiopulmonary bypass. The change from baseline will be compared between the remimazolam and propofol groups. Plasma TNF-α concentration will be measured in pg/mL using the Meso Scale Discovery assay.
Preoperative baseline to 2-4 hours after completion of cardiopulmonary bypass
Change in plasma IL-6 concentration
大体时间:Preoperative baseline to 24 hours after completion of cardiopulmonary bypass
Plasma interleukin-6 (IL-6) concentration will be measured at preoperative baseline and 24 hours after completion of cardiopulmonary bypass. The change from baseline will be compared between the remimazolam and propofol groups. Plasma IL-6 concentration will be measured in pg/mL using the Meso Scale Discovery assay.
Preoperative baseline to 24 hours after completion of cardiopulmonary bypass
Change in plasma IL-10 concentration
大体时间:Preoperative baseline to 24 hours after completion of cardiopulmonary bypass
Plasma interleukin-10 (IL-10) concentration will be measured at preoperative baseline and 24 hours after completion of cardiopulmonary bypass. The change from baseline will be compared between the remimazolam and propofol groups. Plasma IL-10 concentration will be measured in pg/mL using the Meso Scale Discovery assay.
Preoperative baseline to 24 hours after completion of cardiopulmonary bypass
Change in plasma HMGB1 concentration
大体时间:Preoperative baseline through 24 hours after completion of cardiopulmonary bypass
Plasma high mobility group box 1 (HMGB1) concentration will be measured at preoperative baseline, 2-4 hours after completion of cardiopulmonary bypass, and 24 hours after completion of cardiopulmonary bypass. Changes from baseline will be compared between the remimazolam and propofol groups. Plasma HMGB1 concentration will be measured in pg/mL using the Multiplex bead assay.
Preoperative baseline through 24 hours after completion of cardiopulmonary bypass
Change in plasma GFAP concentration
大体时间:Preoperative baseline to 24 hours after completion of cardiopulmonary bypass
Plasma glial fibrillary acidic protein (GFAP) concentration will be measured at preoperative baseline and 24 hours after completion of cardiopulmonary bypass. The change from baseline will be compared between the remimazolam and propofol groups. GFAP will be analyzed using the Single Molecule Array (Simoa) assay.
Preoperative baseline to 24 hours after completion of cardiopulmonary bypass

其他结果措施

结果测量
措施说明
大体时间
Incidence of postoperative delirium
大体时间:Preoperative baseline to postoperative day 7 or before hospital discharge
Postoperative delirium will be assessed using the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). The incidence of postoperative delirium will be compared between the remimazolam and propofol groups.
Preoperative baseline to postoperative day 7 or before hospital discharge

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年10月1日

初级完成 (估计的)

2027年10月1日

研究完成 (估计的)

2027年11月30日

研究注册日期

首次提交

2026年9月7日

首先提交符合 QC 标准的

2026年9月7日

首次发布 (实际的)

2026年9月11日

研究记录更新

最后更新发布 (实际的)

2026年9月17日

上次提交的符合 QC 标准的更新

2026年9月14日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅